Venture NAV Tracker / Private company
Emalex Biosciences, Inc.
Headquarters—
Founded—
Last known round—
Reported valuation—
+272.2% equity-mark dispersion. Horizon Technology Finance Corp carries Emalex Biosciences, Inc. at $3.71/share; Horizon Technology Finance Corp carries it at $13.82/share. Review dates and security types before treating those marks as directly comparable.
Cross-fund comparison
Equity & warrant marks
One latest disclosed mark per fund.
| Fund | Fair value | Security / basis | Implied price / share | Mark age vs round | Methodology / filing |
|---|---|---|---|---|---|
| HRZNHorizon Technology Finance Corp | $656KMar 31, 2026 · source ↗ | equityFair Value | $13.82Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
| HRZNHorizon Technology Finance Corp | $410KMar 31, 2026 · source ↗ | warrantFair Value | $3.71Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
Cross-fund comparison
Debt investments
One latest disclosed debt mark per fund.
| Fund | Security type / basis | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HRZNHorizon Technology Finance Corp | senior secured loanFair Value — Term Loan | $417KMar 31, 2026 · source ↗ | $416KMar 31, 2026 · source ↗ | 99.8%Mar 31, 2026 · source ↗ | Cash rate 11.47%; Index Prime; Margin 4.72%; Floor 9.75%; ETP 5.00%Mar 31, 2026 · source ↗ | May 1, 2026Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | NoMar 31, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.